Publication: Urinary metabolomic profiling in chronic hepatitis B viral infection using gas chromatography/mass spectrometry
Issued Date
2018-03-01
Resource Type
ISSN
2476762X
15137368
15137368
Other identifier(s)
2-s2.0-85044351025
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention. Vol.19, No.3 (2018), 741-748
Suggested Citation
Kanthanadon Dittharot, Paisan Jittorntam, Prapin Wilairat, Abhasnee Sobhonslidsuk Urinary metabolomic profiling in chronic hepatitis B viral infection using gas chromatography/mass spectrometry. Asian Pacific Journal of Cancer Prevention. Vol.19, No.3 (2018), 741-748. doi:10.22034/APJCP.2018.19.3.741 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45214
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Urinary metabolomic profiling in chronic hepatitis B viral infection using gas chromatography/mass spectrometry
Other Contributor(s)
Abstract
© Asian Pacific Journal of Cancer Prevention, 2017. Background: Chronic hepatitis B (CHB) can lead to cirrhosis and hepatocellular carcinoma. The metabolomic profiling has been shown to be associated with pathogenic mechanisms in many medical conditions including CHB. The purpose of this study was to investigate the urine metabolomic profiles in CHB patients by gas chromatography/mass spectrometry (GC/MS). Methods: Urine samples were collected from CHB patients (n = 20) and normal control subjects (n = 20). Metabolite profiles were assessed using GC/MS in conjunction with multivariate statistical analysis, in order to identify biomarker metabolites. Pathway analysis was performed by MetaboAnalyst 3.0 and KEGG database.Results: Twelve out of 377 metabolites were shown to be significantly different between the CHB and normal control groups (p < 0.05). These include palmitic acid, stearic acid, oleic acid, benzoic acid, butanoic acid, cholesterol, glycine, 3-heptanone, 4-heptanone, hexanal, 1-tetradecanol and naphthalene. Multivariate statistical analysis constructed using these expressed metabolites showed CHB patients can be discriminated from healthy controls with high sensitivity (95%) and specificity (85%). All the metabolic perturbations in this disease are associated with pathways of fatty acid, amino acid, bile acid and gut microbial metabolism. Conclusion: CHB patients have a specific urinary metabolomic profile. The abnormalities of fatty acid, amino acid, bile acid, and gut microbial metabolism lead to the development of disease progression. GC/MS-based assay is a promising tool for the metabolomic study in CHB.